Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study

被引：4

作者：

Mauro, Francesca Romana ^{[1
]}

Tedeschi, Alessandra ^{[2
]}

Piciocchi, Alfonso ^{[3
]}

Motta, Marina ^{[4
]}

Iannella, Emilia ^{[5
]}

Farina, Lucia ^{[6
]}

Scarfo, Lydia ^{[7
,8
]}

Marasca, Roberto ^{[9
]}

Coscia, Marta ^{[10
]}

Cortelezzi, Agostino ^{[11
]}

Laurenti, Luca ^{[12
]}

Melpignano, Angela ^{[13
]}

Zinzani, Pier Luigi ^{[14
]}

Molica, Stefano ^{[15
]}

Re, Francesca ^{[16
]}

Andriani, Alessandro ^{[17
]}

Vincelli, Donatella Iolanda ^{[18
,19
]}

Visco, Carlo ^{[20
]}

Gozzetti, Alessandro ^{[21
]}

Orlandi, Ester Maria ^{[22
]}

Trentin, Livio ^{[23
]}

Tani, Monica ^{[24
]}

Califano, Catello ^{[25
]}

Tagariello, Giuseppe ^{[26
]}

Ghia, Paolo ^{[7
,8
]}

Caputo, Maria Denise ^{[27
]}

Salaroli, Adriano ^{[27
]}

Innocenti, Idanna ^{[12
]}

Frustaci, Anna ^{[28
]}

Vitale, Candida ^{[10
]}

Petulla, Marta ^{[29
]}

de Fabritiis, Paolo ^{[5
]}

Vignetti, Marco ^{[3
,27
]}

Fazi, Paola ^{[3
]}

Foa, Robin ^{[30
]}

机构：

[1] Sapienza Univ, Dept Cellular Biotechnol & Hematol, Hematol, Rome, Italy

[2] Osped Niguarda Ca Granda, Dept Hematol, Niguarda Canc Ctr, Milan, Italy

[3] Fdn GIMEMA, Rome, Italy

[4] Spedali Civil Brescia, Dept Hematol, Brescia, Italy

[5] Tor Vergata Univ, S Eugenio Hosp, Dept Hematol, Rome, Italy

[6] Fdn IRCCS Ist Nazl Tumori, Dept Hematol, Milan, Italy

[7] Univ Vita Salute San Raffaele, Strateg Res Programm CLL, Milan, Italy

[8] IRCCS Ist Scientifico San Raffaele, Milan, Italy

[9] Univ Modena & Reggio Emilia, Dept Med & Surg Sci, Hematol Unit, Modena, Italy

[10] AUO Citta Salute & Scienza Torino, Div Hematol, Turin, Italy

[11] Fdn Ca Granda IRCCS Osped Maggiore Policlin, OncoHematol Unit, Milan, Italy

[12] Cathol Univ, Inst Hematol, Sacred Heart, Rome, Italy

[13] Osped A Perrino, Brindisi, Italy

[14] Univ Bologna, Inst Hematol LeA Seragnoli, Bologna, Italy

[15] Azienda Ospedaliera Pugliese Ciaccio, Dept Hematol Oncol, Catanzaro, Italy

[16] Azienda Ospedaliero Univ Parma, Hematol & Bone Marrow Transplantat, Parma, Italy

[17] Nuovo Regina Margherita Hosp, Hematol, Rome, Italy

[18] Azienda Ospedaliera Bianchi Melacrino Morelli, Hematol, Reggio Di Calabria, Italy

[19] GIMEMA, Italian Multiple Myeloma Network, Rome, Italy

[20] San Bortolo Hosp, Dept cell therapy & hematol, Vicenza, Italy

[21] Univ Siena, Hematol, Siena, Italy

[22] Fdn IRCCS Policlin San Matteo, Hematol Hunit, Pavia, Italy

[23] Univ Padua, Dept Med, Hematol & Clin Immunol Branch, Sch Med, Padua, Italy

[24] Santa Maria Croci Hosp, Hematol Unit, Ravenna, Italy

[25] Nocera Pagani, Onco Hematol Unit, Pagani, Italy

[26] Hemophilia & Reg Blood Dis Ctr, Hematol Transfus Serv, Castelfranco Veneto, Italy

[27] Sapienza Univ, Dept Cellular Biotechnol & Hematol, Rome, Italy

[28] Osped Niguarda Ca Granda, Dept Hematol, Milan, Italy

[29] ASST Spedali Civili Brescia, Hematol, Brescia, Italy

[30] Sapienza Univ, Dept Cellular Biotechnol & Hematol, Policlin Umberto, Rome, Italy

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.2038.2038

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2038

引用

页数：5

共 27 条

[21] ALLOGENEIC STEM CELL TRANSPLANTATION VERSUS B-CELL-RECEPTOR INHIBITORS IN 17P DELETION AND/OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: A RETROSPECTIVE COMPARATIVE ANALYSIS OF 'REAL LIFE' APPROACHES TO HIGH RISK PATIENTS
Farina, L.
Scarfo, L.
Bruno, B.
Mazzucchelli, M.
Patriarca, F.
Salvetti, C.
Quaresmini, G.
Medeo, M.
Onida, F.
Reda, G.
Ferrario, A.
Zallio, F.
Vallisa, D.
Magagnoli, M.
Dodero, A.
Mariani, L.
Ghia, P.
Corradini, P.
Montillo, M.
HAEMATOLOGICA, 2017, 102 : 13 - 13
[22] Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus
Visentin, Andrea
Mauro, Francesca Romana
Pietrasanta, Daniela
Fresa, Alberto
Vitale, Candida
Ciolli, Stefania
Cassin, Ramona
Cibien, Francesca
Sportoletti, Paolo
Gentile, Massimo
Rigolin, Gian Matteo
Quaglia, Francesca M.
Murru, Roberta
Gozzetti, Alessandro
Molica, Stefano
Marchetti, Monia
Scarfo, Lydia
Reda, Gianluigi
Coscia, Marta
Laurenti, Luca
Pizzolo, Giovanni
Semenzato, Gianpietro
Foa, Robin
Cuneo, Antonio
Trentin, Livio
BLOOD, 2020, 136
[23] Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: a lifetime economic research study
Yuan Hong
Xichuang Chen
Yuanquan Hong
Xingfang Xiao
Yan Wang
Xiaohong You
Jingyi Mi
Tao Zhou
Panpan Zheng
Zhihu Huang
BMC Health Services Research, 23
[24] Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: a lifetime economic research study
Hong, Yuan
Chen, Xichuang
Hong, Yuanquan
Xiao, Xingfang
Wang, Yan
You, Xiaohong
Mi, Jingyi
Zhou, Tao
Zheng, Panpan
Huang, Zhihu
BMC HEALTH SERVICES RESEARCH, 2023, 23 (01)
[25] Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors
Munir, T.
Hillmen, P.
Sharman, J.
Coutre, S.
Furman, R.
Cheson, B.
Pagel, J.
Barrientos, J.
Zelenetz, A.
Kipps, T.
Flinn, I.
Ghia, P.
Hallek, M.
Coiffier, B.
O'Brien, S.
Tausch, E.
Kreuzer, K.
Jiang, W.
Lazarov, M.
Li, D.
Jahn, T.
Stilgenbauer, S.
BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 : 19 - 19
[26] Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib
Siddiqi, Tanya
Soumerai, Jacob D.
Dorritie, Kathleen A.
Stephens, Deborah M.
Riedell, Peter A.
Arnason, Jon E.
Kipps, Thomas J.
Gillenwater, Heidi H.
Gong, Lucy
Dubovsky, Jason A.
Rytlewski, Julie
Yang, Lin
Wierda, William G.
BLOOD, 2019, 134
[27] Allogeneic Stem Cell Transplantation Versus B-Cell-Receptor Inhibitors in 17p Deletion and/ or Refractory Chronic Lymphocytic Leukemia: A Retrospective Comparative Analysis of ' Real Life' Approaches to High Risk Patients, on Behalf of Rete Ematologica Lombarda (REL) and Gruppo Italiano Trapianto Di Midollo Osseo (GITMO)
Farina, Lucia
Patriarca, Francesca
Mazzucchelli, Maddalena
Salvetti, Chiara
Quaresmini, Giulia
Medeot, Marta
Vincenti, Daniele
Reda, Gianluigi
Ferrario, Andrea
Zallio, Francesco
Dodero, Anna
Bruno, Benedetto
Corradini, Paolo
Montillo, Marco
BLOOD, 2016, 128 (22)

← 1 2 3 →